全文获取类型
收费全文 | 190篇 |
免费 | 14篇 |
国内免费 | 5篇 |
专业分类
儿科学 | 3篇 |
基础医学 | 36篇 |
口腔科学 | 2篇 |
临床医学 | 17篇 |
内科学 | 74篇 |
神经病学 | 9篇 |
特种医学 | 3篇 |
外科学 | 23篇 |
综合类 | 5篇 |
预防医学 | 8篇 |
药学 | 15篇 |
肿瘤学 | 14篇 |
出版年
2023年 | 3篇 |
2022年 | 7篇 |
2021年 | 7篇 |
2020年 | 10篇 |
2019年 | 4篇 |
2018年 | 12篇 |
2017年 | 5篇 |
2016年 | 1篇 |
2015年 | 5篇 |
2014年 | 10篇 |
2013年 | 7篇 |
2012年 | 20篇 |
2011年 | 12篇 |
2010年 | 9篇 |
2009年 | 10篇 |
2008年 | 15篇 |
2007年 | 15篇 |
2006年 | 6篇 |
2005年 | 16篇 |
2004年 | 9篇 |
2003年 | 12篇 |
2002年 | 9篇 |
2001年 | 2篇 |
2000年 | 1篇 |
1995年 | 1篇 |
1883年 | 1篇 |
排序方式: 共有209条查询结果,搜索用时 31 毫秒
101.
Diabetes and pre-diabetes are major contributors to cardiovascular mortality and morbidity. Insulin resistance is a key pathophysiological determinant of the metabolic and vascular abnormalities noted in these disorders. Ineffective vascular repair is likely to be an important contributor to the development of endothelial dysfunction, and subsequently atherosclerosis, in patients with diabetes. Beyond the systemic effects of the insulin resistant phenotype, including factors such as dysglycaemia and inflammation, cellular insulin resistance is emerging as an important factor in diabetic vascular disease. Disordered signal transduction via the PI3-kinase/Akt and MAP-kinase cascades is a hallmark of cellular insulin resistance, and such changes have been linked with both endothelial dysfunction and impaired angiogenesis. In this review we highlight the importance of insulin resistance to vascular repair and regeneration, discuss important cross-talk between the intracellular signalling of insulin and key pro-angiogenic molecules, and link these concepts to common patterns of vascular disease. 相似文献
102.
Nagata M Nuckolls GH Wang X Shum L Seki Y Kawase T Takahashi K Nonaka K Takahashi I Noman AA Suzuki K Slavkin HC 《BONE》2011,48(4):847-856
Activation of osteoblastic bone anabolism in the calvarial sutures is considered to be the essential pathologic condition underlying mutant FGFR2-related craniofacial dysostosis. However, early clinical investigations indicated that abnormal cartilage development in the cranial base was rather a primary site of abnormal feature in Apert Syndrome (AS). To examine the significance of cartilaginous growth of the cranial base in AS, we generated a transgenic mouse bearing AS-type mutant Fgfr2IIIc under the control of the Col2a1 promoter-enhancer (Fgfr2IIIc(P253R) mouse). Despite the lacking expression of Fgfr2IIIc(P253R) in osteoblasts, exclusive disruption of chondrocytic differentiation and growth reproduced AS-like acrocephaly accompanied by short anterior cranial base with fusion of the cranial base synchondroses, maxillary hypoplasia and synostosis of the calvarial sutures with no significant abnormalities in the trunk and extremities. Gene expression analyses demonstrated upregulation of p21, Ihh and Mmp-13 accompanied by modest increase in expression of Sox9 and Runx2, indicating acceleration of chondrocytic maturation and hypertrophy in the cranial base of the Fgfr2IIIc(P253R) mice. Furthermore, an acquired affinity and specificity of mutant FGFR2IIIc(P253R) receptor with FGF2 and FGF10 is suggested as a mechanism of activation of FGFR2 signaling selectively in the cranial base. In this report, we strongly suggest that the acrocephalic feature of AS is not alone a result of the coronal suture synostosis, but is a result of the primary disturbance in growth of the cranial base with precocious endochondral ossification. 相似文献
103.
104.
105.
106.
Noman H Khasati Ali Machaal Jim Barnard Nizar Yonan 《Journal of cardiothoracic surgery》2007,2(1):13-5
Background
The decline in the number of suitable donor hearts has led to an increasing interest in the use of previously unacceptable donors. In the United Kingdom, if one centre declines a donor heart on medical grounds it may be offered to other centres. This multi-centre study aimed to evaluate the outcome of recipients of donor hearts considered medically unsuitable for transplantation by one centre that were used in other centres. 相似文献107.
108.
Over the last several decades, the incidence of adenocarcinoma of the gastroesophageal junction (GEJ) has been increasing in developed countries. Although complete surgical resection remains the cornerstone of treatment for resectable disease, long‐term outcomes are poor and recurrence rates are high with surgery alone in patients presenting with locally advanced disease. Multimodal therapy has been shown to improve survival; however, the optimal therapeutic approach remains controversial, and practices vary across the world. Preoperative chemoradiotherapy is generally used in the U.S., whereas perioperative chemotherapy without radiation is favored in most European countries. In this review, we discuss why the treatment of locally advanced GEJ tumors remains controversial, examine the evidence for various multimodal approaches, discuss their respective pros and cons, evaluate the role of radiation therapy, highlight some ongoing and planned clinical trials, and suggest areas that need further research. 相似文献
109.
Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease 总被引:7,自引:0,他引:7
Esters N Vermeire S Joossens S Noman M Louis E Belaiche J De Vos M Van Gossum A Pescatore P Fiasse R Pelckmans P Reynaert H Poulain D Bossuyt X Rutgeerts P;Belgian Group of Infliximab Expanded Access Program in Crohn's Disease 《The American journal of gastroenterology》2002,97(6):1458-1462
OBJECTIVES: The use of monoclonal anti-tumor necrosis factor (TNF) antibodies (infliximab, Remicade) is a new therapeutic approach for severe refractory luminal or fistulizing, Crohn's disease (CD). However, up to 30% of patients do not respond to this treatment. So far, no parameters predictive of response to anti-TNF have been identified. Our aim was to determine whether serological markers ASCA (anti-Saccharomyces cerevisiae antibodies) or pANCA (perinuclear antineutrophil cytoplasmic antibodies) could identify Crohn's patients likely to benefit from anti-TNF therapy. METHODS: Serum samples of 279 CD patients were analyzed for ASCA and pANCA before anti-TNF therapy. A blinded physician determined clinical response at week 4 (refractory luminal CD) or week 10 (fistulizing CD) after the first infusion of infliximab (5 mg/kg). RESULTS: Overall, there was no relationship between ASCA or pANCA and response to therapy. However, lower response rates were observed for patients with refractory intestinal disease carrying the pANCA+/ASCA- combination, although this lacked significance (p = 0.067). CONCLUSIONS: In this cohort of infliximab-treated patients, neither ASCA nor pANCA could predict response to treatment. However, the combination pANCA+/ASCA- might warrant further investigation for its value in predicting nonresponse in patients with refractory luminal disease. 相似文献
110.
Mohamed Azmi Hassali Min-Wei Ching Zuraidah Mohd Yusoff Zanariah Hussein Alian A. Alrasheedy Saleh Karamah AL-Tamimi Fahad Saleem Noman ul Haq Hisham Aljadhey Tahir Khan 《Zeitschrift fur Gesundheitswissenschaften》2014,22(1):3-11